Surge, a Paris-based company specializing in high-level immune system analytics, announced on Thursday that it had secured €7.5 million in a new funding round.
This funding round was led by Eurazeo, with participation from Kima, Teamact, and MH Innov, with historic funds Boutique Venture, HCVC, and 50 Partners Sante ( It also received support from 50 Partners Santé.
The fundraising will be complemented by grants from BPI, including support for deep technology development and future investment programs, for which Surge was selected as an awardee.
The French company will use the funds to accelerate development and begin commercial expansion.
This capital will help the company open SurgeLab, a laboratory for immune biomarker discovery, and finalize the industrialization of PreCyte.
Surge: Pursuing Detoxification of the Immune System
Founded by Brice Gaudilliere and Julien Hedou, Surge is on a mission to revolutionize precision medicine.
The company claims that the launch of PreCyte has achieved a milestone in its long-term strategy to develop a complete ecosystem of precision medicine tools.
In partnership with several renowned institutions, including Foch Hospital and AP-HP, Surge has completed the first large-scale clinical trial validating PreCyte, a test to predict postoperative complications in 283 patients undergoing major surgery.
PreCyte’s initial results show up to three times higher predictive power than existing solutions.
Surge’s goal with PreCyte is not only to predict postoperative complications, but also to pave the way for future precision medicine.
“Working with an internationally renowned institution to validate our products represents an important step in the mission we have set for ourselves. PreCyte’s goal is not only to predict postoperative complications, but also to pave the way for future precision medicine. By revolutionizing predictive approaches to surgery through immune system analysis, we can envision real changes in healthcare pathways to significantly reduce surgery-related risks. Additionally, this research gives us the opportunity to present our innovative approach to other medical or interventional specialties, opening up new development prospects for the future,” says Julien Hédou, co-founder and CEO of Surge. .
Surge’s AI technology
Additionally, Surge’s AI technology has made significant advancements through the development of a patented algorithm called Stabl, which identifies sets of rare, reliable biomarkers and transforms high-dimensional data into clinically relevant signatures.
This, the company claims, will enable the development of truly personalized medicines.
“Stabl represents an important advance in the use of AI for biomarker discovery. Before Stabl arrived, identifying a reliable predictive signature with fewer than 20 biomarkers was a difficult, if not impossible, task. Stabl is changing the game by providing powerful, effective solutions that will benefit both academic institutions and players in the biotechnology and pharmaceutical sectors. This breakthrough is the result of years of research and represents a major advance in our quest to understand and utilize biomarkers,” says Brice Gaudillière, co-founder of Surge and associate professor at Stanford University in the US.
SurgeLab: Individualized Immune Signal Acquisition
The company also founded SurgeLab, an analytical laboratory specializing in immune system detoxification.
This unique platform analyzes thousands of parameters per blood sample, providing a high-resolution map of the immune system.
Surge is already deploying the platform’s analytics capabilities with multiple research institutions to deliver unprecedented information-dense results.
“The launch of SurgeLab is a major advancement in our ability to understand the immune system. As partners, this cutting-edge technology allows us to explore human biology in unprecedented ways, delivering unparalleled accuracy and depth of analysis. This is possible thanks to Surge’s unique approach to AI,” says Ina Stelzer, assistant professor at the University of California, San Diego.
investor
Eurazeo is a European investment group that manages diversified assets worth €35 billion, of which €24 billion are invested in a portfolio of approximately 600 companies on behalf of third parties.
The group specializes in private equity, private debt, real estate and infrastructure assets, providing support to companies of all sizes. With over 400 employees, deep sector expertise and access to global markets, the Group is committed to leveraging its strengths for the benefit of its customers.
Eurazeo has offices in Paris, New York, London, Frankfurt, Berlin, Milan, Madrid, Luxembourg, Shanghai, Seoul, Singapore and Sao Paulo.
“With a solid scientific and technological foundation, Surge has already demonstrated the feasibility of its biomarker discovery platform to address specific clinical needs and integrate precision medicine into surgical care. Impressed with the team’s speed and precision of execution, we are excited to support Surge as their challenge is to bring the PreCyte solution to as many people as possible in the coming months and generalize the technology approach to new clinical use cases. I’m delighted. It is an exciting dual challenge between contributing to academic research and innovating healthcare pathways,” says Maxime Huerre, Vice President of Ventures at Eurazeo.